The September 29, 2026 publication of TRIUMPH-2 adds detailed phase 3 evidence for retatrutide in adults with both obesity and type 2 diabetes. In 1,152 participants, the investigational GIP, GLP-1, and glucagon receptor agonist produced dose-related weight loss and meaningful HbA1c reductions over 80 weeks.
The ZUPREME-1 Phase 2 publication reports that the investigational once-weekly amylin analogue petrelintide produced up to 10.7% mean weight loss at week 42 versus 1.7% with placebo in 493 adults with obesity or overweight. The placebo-controlled trial also reported nausea more often with petrelintide, while direct comparisons with GLP-1 medicines remain unavailable.
The September 29, 2026 New England Journal of Medicine publication of TRIUMPH-1 provides the first detailed peer-reviewed phase 3 results for retatrutide in obesity. In 2,339 adults without diabetes, the investigational triple agonist produced dose-dependent weight loss over 80 weeks, while prespecified subgroups reported improvements in knee osteoarthritis pain and obstructive sleep apnea. The findings are substantial, but they do not establish FDA approval, long-term cardiovascular benefit, or superiority over approved medicines in a head-to-head trial.
A 2026 mechanistic study suggests liraglutide can use different brain, pancreatic, liver, and peripheral pathways as metabolic dysfunction progresses. Human-islet and mouse findings explain biology, not individualized treatment selection.
A September 2026 peer-reviewed study provides the first detailed human data on ribupatide, also known as HRS9531. The dual GLP-1/GIP receptor agonist was tested in 90 healthy Chinese adults across single- and multiple-ascending-dose cohorts. After four weekly doses, mean weight loss ranged from 4.3 to 7.7 kilograms, while no serious treatment-emergent adverse events or deaths were reported. The findings are early phase 1 evidence, not proof of long-term obesity-treatment effectiveness.
The GRABS trial is testing tirzepatide after gastric bypass in adults who remain obese despite Roux-en-Y surgery. Published in September 2026, the study is important because post-bariatric patients have often been excluded from major obesity-drug trials. The paper reports the trial’s rationale, design, and baseline cohort—not its final weight-loss results.
The phase 3 OUTSTAND-1 trial provides the strongest human evidence yet for safiglipron, an oral small-molecule GLP-1 receptor agonist formerly known as HRS-7535. In 284 Chinese adults with early type 2 diabetes, once-daily safiglipron produced placebo-adjusted HbA1c reductions of 1.20 to 1.45 percentage points after 32 weeks. The trial also tested an important practical advantage: unlike oral semaglutide, the tablet was studied without fasting or special food and water rules. However, gastrointestinal adverse events were common, weight loss was modest compared with obesity-focused GLP-1 trials, and the results do not yet establish cardiovascular or kidney-outcome benefits.
Two randomized phase 2 trials published in Neuropsychopharmacology on September 5, 2026 found that satoprodil, also known as BI 1569912, did not reduce depressive symptoms beyond placebo when used alone or alongside standard antidepressants. The result is an important test of non-ketamine glutamate drug development: the compound was generally tolerated, but the GluN2B-selective mechanism did not deliver a meaningful antidepressant signal in these studies.
Reports of vision problems in GLP-1 users involve different medical questions. This evidence review separates nutritional neurological injury linked to severe poor intake from NAION, a rare optic-nerve disorder, and explains what current studies do and do not prove.
A July 2026 DOJ resolution involving Alibaba and a Utah indictment illustrate how opaque peptide supply chains, relabeling, and marketplace systems can expose consumers to unverified products.
